3.1.5 Ritlecitinib (PF-06651600) and Brepocitinib (PF-06700841) Ritlecitinib, an irreversible inhibitor of JAK3 and tyrosine kinase applicable to the treatment of moderate-to-severe RA (40) and Brepocitinib, a TYK2/JAK1 inhibitor, are currently undergoing evaluation of their efficacy and safety profile in active NSV in combination with phototherapy (NCT03715829) (41)
Macone AB, Caruso BK, Leahy RG, Donatelli J, Weir S, Draper MP, et al
Mehta, D., Sharma, N., Bansal, V., Sangwan, R
Internal hemorrhoids may cause bleeding during bowel movements, often appearing as bright red blood on toilet paper or in the toilet bowl
Notably, Bifidobacterium, Lactobacillus, Akkermansia , and certain butyrate-producing bacteria play pivotal roles in the gut-brain axis
Cell 156 (1-2), 317331